• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form NT 10-K filed by VivoSim Labs Inc.

    6/29/26 4:05:11 PM ET
    $VIVS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $VIVS alert in real time by email
    NT 10-K 1 vivsnt10k33126.htm NT 10-K NT 10-K

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    SEC FILE NUMBER

    Washington, D.C. 20549

    001-35996

    FORM 12b-25

    CUSIP NUMBER

    68620A302

    NOTIFICATION OF LATE FILING

    (Check One):

    ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D

    ☐ Form N-CEN ☐ Form N-CSR

    For Period Ended: March 31, 2026

    ☐ Transition Report on Form 10-K

    ☐ Transition Report on Form 20-F

    ☐ Transition Report on Form 11-K

    ☐ Transition Report on Form 10-Q

    For the Transition Period Ended:


    Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

    If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

    PART I - REGISTRANT INFORMATION

    VivoSim Labs, Inc.

    Full Name of Registrant

     

    Former Name if Applicable

    11555 Sorrento Valley Rd, Suite 100

    Address of Principal Executive Office (Street and Number)

    San Diego, California 92121

    City, State and Zip Code

    PART II - RULES 12b-25(b) AND (c)

    If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

     

    ☒

    (a)

    The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;

    (b)

    The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and

    (c)

    The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

    PART III - NARRATIVE

    State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

     

    VivoSim Labs, Inc. (the “Registrant”) has determined that it is unable, without unreasonable effort or expense, to file its Annual Report on Form 10-K for the fiscal year ended March 31, 2026 (the “Form 10-K”) by June 29, 2026, the prescribed due date, because it requires more time to gather necessary information for the preparation and finalization of its financial statements and other disclosures to be included in the Form 10-K. The Registrant is working diligently to complete the Form 10-K as soon as practicable, which the Registrant anticipates will not be later than the fifteenth calendar day following the prescribed due date for the Form 10-K, or July 14, 2026.

    PART IV - OTHER INFORMATION


    (1)

    Name and telephone number of person to contact in regard to this notification

    Norman Staskey, Chief Financial Officer

    (858)

    224-1000

    (Name)

    (Area Code)

    (Telephone Number)

    (2)

    Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). ☒ Yes ☐ No

    (3)

    Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? ☐ Yes ☒ No

    If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

     


     

    VivoSim Labs, Inc.

    (Name of Registrant as Specified in Charter)

    has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

    Date: June 29, 2026

    By:

    /s/ Norman Staskey

    Norman Staskey

    Chief Financial Officer

     

     

     


    Get the next $VIVS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VIVS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $VIVS
    SEC Filings

    View All

    VivoSim Labs Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities

    8-K - VivoSim Labs, INC. (0001497253) (Filer)

    7/17/26 8:45:07 AM ET
    $VIVS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-K filed by VivoSim Labs Inc.

    10-K - VivoSim Labs, INC. (0001497253) (Filer)

    7/14/26 4:50:19 PM ET
    $VIVS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form NT 10-K filed by VivoSim Labs Inc.

    NT 10-K - VivoSim Labs, INC. (0001497253) (Filer)

    6/29/26 4:05:11 PM ET
    $VIVS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VIVS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    VivoSim Enters China with First Commercial Sales of NAMkind™ Toxicology Screening and Efficacy Testing Services

    SAN DIEGO, July 21, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (NASDAQ:VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety, today announced its first commercial sales in China, opening a significant new market for its NAMkind™ testing services. VivoSim delivers both toxicology and efficacy testing built on its 3D human tissue models of the liver and gastrointestinal (GI) tract. The two initial engagements, with a leading Shanghai-based oncology biotech and a large Chengdu-based pharmaceutical company, represent the Company’s first paid programs on the Chinese mainland and a milestone in VivoSim’s expansion across Asia-

    7/21/26 8:05:00 AM ET
    $VIVS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    VivoSim Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Healthcare Focused Institutional Investor

    SAN DIEGO, July 16, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (NASDAQ:VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models for preclinical safety, today announced that it has entered into a securities purchase agreement with a single healthcare focused institutional investor for the purchase and sale of 4,705,883 shares of common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 4,705,883 shares of common stock at an effective combined price of $0.85 per share and accompanying common warrant for aggregate gross proceeds of approximately $4.0 million, before deducting placement agent fe

    7/16/26 8:30:00 AM ET
    $VIVS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Three Biotechs Deliver Catalysts to Watch

    DENVER, July 15, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – Today’s announcements from NeOnc Technologies (NASDAQ:NTHI), Ernexa Therapeutics (NASDAQ:ERNA), and VivoSim Labs (NASDAQ:VIVS) highlight three distinct pathways to potential value creation. NeOnc Technologies NeOnc Technologies (NASDAQ:NTHI) announced that it has received written feedback from the U.S. Food and Drug Administration regarding the chemistry, manufacturing, and controls (CMC) development program for its lead drug candidate, NEO212, a novel temozolomide-perillyl alcohol conjugate being developed for malignant brain tumors and other central nervous system cancers. Rather than proceeding with its scheduled Type B

    7/15/26 10:42:42 AM ET
    $NTHI
    $ERNA
    $VIVS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $VIVS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Cohen Douglas Jay was granted 15,000 shares, increasing direct ownership by 262% to 20,732 units (SEC Form 4)

    4 - VivoSim Labs, INC. (0001497253) (Issuer)

    1/29/26 7:59:37 PM ET
    $VIVS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    EXECUTIVE CHAIRMAN Murphy Keith was granted 15,000 shares, increasing direct ownership by 136% to 26,053 units (SEC Form 4)

    4 - VivoSim Labs, INC. (0001497253) (Issuer)

    1/29/26 7:59:09 PM ET
    $VIVS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Milhous Alison Tjosvold was granted 15,000 shares, increasing direct ownership by 306% to 19,899 units (SEC Form 4)

    4 - VivoSim Labs, INC. (0001497253) (Issuer)

    1/29/26 7:51:55 PM ET
    $VIVS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VIVS
    Leadership Updates

    Live Leadership Updates

    View All

    VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales

    SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (NASDAQ:VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety, today announced the appointment of Dr. Arumugham (Ragoo) Raghunathan, PhD as Vice President of Global Sales. Based in the Greater Boston area, Dr. Raghunathan will lead commercial expansion and secure strategic partnerships with biopharma innovators, established pharmaceutical companies, CROs/CDMOs, and research institutions. His focus will be on delivering VivoSim's liver and gastrointestinal (GI) toxicity solutions for earlier de-risking of drug candidates and clearer feasibility decisions thro

    3/3/26 8:05:00 AM ET
    $VIVS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    VivoSim Labs Appoints Amar Sethi, M.D., Ph.D. as Chief Scientific Officer

    SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (NASDAQ:VIVS) (the "Company" or "VivoSim Labs"), a pharmaceutical and biotechnology services company that is focused on providing testing of drugs and drug candidates in three-dimensional ("3D") human tissue models of liver and intestine, announces it has appointed Amar Sethi, M.D., Ph.D. as its Chief Scientific Officer. Dr. Sethi is a transformational R&D executive with three decades of experience encompassing pharmaceutical drug development, CRO leadership, translational medicine, and diagnostic innovation. He has led global Phase I–IV clinical programs, FDA breakthrough and orphan drug designations, BLA filings, and advance

    1/6/26 8:05:00 AM ET
    $VIVS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer

    SAN DIEGO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (NASDAQ:VIVS) (the "Company" or "VivoSim Labs"), a pharmaceutical and biotechnology services company that is focused on providing testing of drugs and drug candidates in three-dimensional ("3D") human tissue models of liver and intestine, announced today that it has appointed Tony Lialin as its Chief Commercial Officer. Mr. Lialin brings more than two decades of experience turning breakthrough life science platforms into scalable, predictable revenue. He has built commercial teams from the ground up, forged strategic pharma partnerships, and helped scale multiple businesses that were later acquired by leading industry players

    8/14/25 8:05:12 AM ET
    $VIVS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care